Podcasts about ilc

JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast." Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are thrilled to be joined by Dr. Julia Foldi, Assistant Professor of Medicine in the Division of Hematology-Oncology at University of Pittsburgh School of Medicine and the Magee-Womens Hospital of the UPMC. She is also the lead and corresponding author of the JCO Precision Oncology article entitled "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma of the Breast." At the time of this recording, our guest's disclosures will be linked in the transcript. Julia, welcome to our podcast, and thank you for joining us today. Dr. Julia Foldi: Thank you so much for having me. It is a pleasure. Dr. Rafeh Naqash: Again, your manuscript and project address a few interesting things, so we will start with the basics, since we have a broad audience that comprises trainees, community oncologists, and obviously precision medicine experts as well. So, let us start with invasive lobular breast carcinoma. I have been out of fellowship for several years now, and I do not know much about invasive lobular carcinoma. Could you tell us what it is, what some of the genomic characteristics are, why it is different, and why it is important to have a different way to understand disease biology and track disease status with this type of breast cancer? Dr. Julia Foldi: Yes, thank you for that question. It is really important to frame this study. So, lobular breast cancers, which we shorten to ILC, are the second most common histologic subtype of breast cancer after ductal breast cancers. ILC makes up about 10 to 15 percent of all breast cancers, so it is relatively rare, but in the big scheme of things, because breast cancer is so common, this represents actually over 40,000 new diagnoses a year in the US of lobular breast cancers. What is unique about ILC is it is characterized by loss of an adhesion molecule, E-cadherin. It is encoded by the CDH1 gene. What it does is these tumors tend to form discohesive, single-file patterns and infiltrate into the tumor stroma, as opposed to ductal cancers, which generally form more cohesive masses. As we generally explain to patients, ductal cancers tend to form lumps, while lobular cancers often are not palpable because they infiltrate into the stroma. This creates several challenges, particularly when it comes to imaging. In the diagnostic setting, we know that mammograms and ultrasounds have less sensitivity to detect lobular versus ductal breast cancer. When it comes to the metastatic setting, conventional imaging techniques like CT scans have less sensitivity to detect lobular lesions often. One other unique characteristic of ILC is that these tumors tend to have lower proliferation rates. Because our glucose-based PET scans depend on glucose uptake of proliferating cells, often these tumors also are not avid on conventional FDG-PET scans. It is a challenge for us to monitor these patients as they go through treatment. If you think about the metastatic setting, we start a new treatment, we image people every three to four cycles, about every three months, and we combine the imaging results with clinical assessment and tumor markers to decide if the treatment is working. But if your imaging is not reliable, sometimes even at diagnosis, to really detect these tumors, then really, how are we following these patients? This is really the unique challenge in the metastatic setting in patients with lobular breast cancer: we cannot rely on the imaging to tell if patients are responding to treatment. This is where liquid biopsies are really, really important, and as the field is growing up and we have better and better technologies, lobular breast cancer is going to be a field where they are going to play an important role. Dr. Rafeh Naqash: Thank you for that easy-to-understand background. The second aspect that I would like to have some context on, to help the audience understand why you did what you did, is ctDNA, tumor informed and non-informed. Could you tell us what these subtypes of liquid biopsies are and why you chose a tumor informed assay for your study? Dr. Julia Foldi: Yes, it is really important to understand these differences. As you mentioned, there are two main platforms for liquid biopsy assays, circulating tumor DNA assays. I think what is more commonly used in the metastatic setting are non-tumor informed assays, or agnostic assays. These are generally next-generation sequencing-based assays that a lot of companies offer, like Guardant, Tempus, Caris, and FoundationOne. These do not require tumor tissue; they just require a blood sample, a plasma sample, essentially. The next-generation sequencing is done on cell-free DNA that is extracted from the plasma, and it is looking for any cell-free DNA and essentially, figuring out what part of the cell-free DNA comes from the tumor is done through a bioinformatics approach. Most of these assays are panel tests for cancer-associated mutations that we know either have therapeutic significance or biologic significance. So, the results we receive from these tests generally read out specific mutations in oncogenic genes, or sometimes things like fusions where we have specific targeted drugs. Some of the newer assays can also read out tumor fraction; for example, the newest generation Guardant assay that is methylation-based, they can also quantify tumor fraction. But the disadvantage of the tumor agnostic approach is that it is a little bit less sensitive. Opposed to that, we have our tumor informed tests, and these require tumor tissue. Essentially, the tumor is sequenced; this can either be whole exome or whole genome sequencing. The newer generation assays are now using whole genome sequencing of the tumor tissue, and a personalized, patient-specific panel of alterations is essentially barcoded on that tumor tissue. This can be either structural variants or it can be mutations, but generally, these are not driver mutations, but sort of things that are present in the tumor tissue that tend to stay unchanged over time. For each particular patient, a personalized assay, if you want to call it a fingerprint or barcode, is created, and then that is what then is used to test the plasma sample. Essentially, you are looking for that specific cancer in the blood, that barcode or fingerprint in the blood. Because of this, this is a much more sensitive way of looking for ctDNA, and obviously, this detects only that particular tumor that was sequenced originally. So, it is much more sensitive and specific to that tumor that was sequenced. You can argue for both approaches in different settings. We use them in different settings because they give us different information. The tumor agnostic approach gives us mutations, which can be used to determine what the next best therapy to use is, while the tumor informed assay is more sensitive, but it is not going to give us information on therapeutic targets. However, it is quantified, and we can follow it over time to see how it changes. We think that it is going to tell us how patients respond to treatment because we see our circulating tumor DNA levels rise and fall as the cancer burden increases or decreases. We decided to use the tumor informed approach in this particular study because we were really interested in how to determine if patients are having response to treatment versus if they are going to progress on their treatment, more so than looking for specific mutations. Dr. Rafeh Naqash: When you think about these tumor informed assays and you think about barcoding the mutations on the original tumor that you try to track or follow in subsequent blood samples, plasma samples, in your experience, if you have done it in non-lobular cancers, do you think shedding from the tumor has something to do with what you capture or how much you capture? Dr. Julia Foldi: Absolutely. I think there are multiple factors that go into whether someone has detectable ctDNA or not, and that has to do with the type of cancer, the location, right, where is the metastatic site? This is something that we do not fully understand yet: what are tumors that shed more versus not? There is also clearance of ctDNA, and so how fast that clearance occurs is also something that will affect what you can detect in the blood. ctDNA is very short-lived, only has a half-life of hours, and so you can imagine that if there is little shedding and a lot of excretion, then you are not going to be detecting a lot of it. In general, in the metastatic setting, we see that we can detect ctDNA in a lot of cases, especially when patients are progressing on treatment, because we imagine their tumor burden is higher at that point. Even with the non-tumor informed assays, we detect a lot of ctDNA. Part of this study was to actually assess: what is the proportion of patients where we can have this information? Because if we are only going to be able to detect ctDNA in less than 50 percent of patients, then it is not going to be a useful method to follow them with. Because this field is new and we have not been using a lot of tumor informed assays in the metastatic setting, we did not really know what to expect when we set out to look at this. We did not know what was going to be the baseline detection rate in this patient population, so that was one of the first things that we wanted to answer. Dr. Rafeh Naqash: Excellent. Now going to this manuscript in particular, what was the research question, what was the patient population, and what was the strategy that you used to investigate some of these questions? Dr. Julia Foldi: So, we partnered with Natera, and the reason was that their Signatera tumor-informed assay was the first personalized, tumor-informed, really an MRD assay, minimal residual disease detection assay. It has been around the longest and has been pretty widely used commercially already, even though some of our data is still lacking. but we know that people are using this in the real world. We wanted to gather some real-world data specifically in lobular patients. So, we asked Natera to look at their database of commercial Signatera testing and look for patients with stage 4 lobular breast cancer. The information all comes from the submitting physicians sending in pathologic reports and clinical notes, and so they have that information from the requisitions essentially that are sent in by the ordering physician. We found 66 patients who were on first-line or close to first-line endocrine-based therapies for their metastatic lobular breast cancer and had serial collections of Signatera tests. The way we defined baseline was that the first Signatera had to be sent within three months of starting treatment. So, it is not truly baseline, but again, this is a limitation of looking at real-world data is that you are not always going to get the best time point that you need. We had over 350 samples from those 66 patients, again longitudinal ctDNA samples, and our first question was what is the baseline detection rate using this tumor informed assay? Then, most importantly, what is the concordance between changes in ctDNA and clinical response to treatment? That is defined by essentially radiologic response to treatment. Dr. Rafeh Naqash: Interesting. So, what were some of your observations in terms of ctDNA dynamics, whether baseline levels made a difference, whether subsequent levels at different time points made a difference, or subsequent levels at, let us say, cycle three made a difference? Were there any specific trends that you saw? Dr. Julia Foldi: So, first, at baseline, 95 percent of patients had detectable ctDNA, which is, I think, a really important data point because it tells us that this can be a really useful test. If we can detect it in almost all patients before they start treatment, we are going to be able to follow this longitudinally. And again, these were not true baseline samples. So, I think if we look really at baseline before starting treatment, almost all patients will have detectable ctDNA in the metastatic setting. The second important thing we saw was that disease progression correlated very well with increase in ctDNA. So, in most patients who had disease progression by imaging, we saw increase in ctDNA. Conversely, in most patients who had clinical benefit from their treatment, so they had a response or stable disease, we saw decrease in ctDNA levels. It seems that what we call molecular response based on ctDNA is tracking very nicely along with the radiographic response. So, those were really the two main observations. Again, this is a small cohort, limited by its real-world nature and the time points that ctDNA assay was sent was obviously not mandated. This is a real-world data set, and so we could not really look at specific time points like you asked about, let us say, cycle three of therapy, right? We did not have all of the right time points for all of the patients. But what we were able to do was to graph out some specific patient scenarios to illustrate how changes in ctDNA correlate with imaging response. I can talk a little bit about that. Dr. Rafeh Naqash: That was going to be my question. Did you see patients who had serial monitoring using the tumor informed ctDNA assay where the assay became positive a few months before the imaging? Did you have any of those kinds of observations? Dr. Julia Foldi: Yes, so I think this is where the field is going: are we able to use this technology to maybe detect progression before it becomes clinically apparent? Of course, there are lots of questions about: does that really matter? But it seems like, based on some of the patient scenarios that we present in the paper, that this testing can do that. So, we had a specific scenario, and this is illustrated in a figure in the paper, really showing the treatment as well as the changes in ctDNA, tumor markers, and also radiographic response. So, this particular patient was on first-line endocrine therapy and CDK4/6 inhibitor with palbociclib. Initially, she had a low-level detectable ctDNA. It became undetectable during treatment, and the patient had a couple of serial ctDNA assays that were negative, so undetectable. And then we started, after about seven months on this combination therapy, the ctDNA levels started rising. She actually had three serial ctDNA assays with increasing level of ctDNA before she even had any imaging tests. And then around the time that the ctDNA peaked, this patient had radiographic evidence of progression. There was also an NGS-based assay sent to look for specific mutations at that point. The patient was found to have an ESR1 mutation, which is very common in this patient population. She was switched to a novel oral SERD, elacestrant, and the ctDNA fell again to undetectable within the first couple months of being on elacestrant. And then a very similar thing happened: while she was on this second-line therapy, she had three serial negative ctDNA assays, and then the fourth one was positive. This was two months before the patient had a scan that showed progression again. Dr. Rafeh Naqash: And Julia, like you mentioned, this is a small sample size, limited number of patients, in this case, one patient case scenario, but provides insights into other important aspects around escalation or de-escalation of therapy where perhaps ctDNA could be used as an integral biomarker rather than an exploratory biomarker. What are some of your thoughts around that and how is the breast cancer space? I know like in GI and bladder cancer, there has been a significant uptrend in MRD assessments for therapeutic decision making. What is happening in the breast cancer space? Dr. Julia Foldi: So, super interesting. I think this is where a lot of our different fields are going. In the breast cancer space, so far, I have seen a lot of escalation attempts. It is not even necessarily in this particular setting where we are looking at dynamics of ctDNA, but in the breast cancer world, of course, we have a lot of data on resistance mutations. I mentioned ESR1 mutation in a particular patient in our study. ESR1 mutations are very common in patients with ER-positive breast cancer who are on long-term endocrine therapy, and ESR1 mutations confer resistance to aromatase inhibitors. So, that is an area that there has been a lot of interest in trying to detect ESR1 mutations earlier and switching therapy early. So, this was the basis of the SERENA-6 trial, which was presented last year at ASCO and created a lot of excitement. This was a trial where patients had non-tumor-informed NGS-based Guardant assay sent every three to six months while they were on first-line endocrine therapy with a CDK4/6 inhibitor. If they had an ESR1 mutation detected, they were randomized to either continue the same endocrine therapy or switch to an oral SERD. The trial showed that the population of patients who switched to the oral SERD did better in terms of progression-free survival than those who stayed on their original endocrine therapy. There are a lot of questions about how to use this in routine practice. Of course, it is not trivial to be sending a ctDNA assay every three to six months. The rate of detection of these mutations was relatively low in that study; again, the incidence increases in later lines of therapy. So, there are a lot of questions about whether we should be doing this in all of our first-line patients. The other question is, even the patients who stayed on their original endocrine therapy were able to stay on that for another nine months. So, there is this question of: are we switching patients too early to a new line of therapy by having this escalation approach? So, there are a lot of questions about this. As far as I know, at least in our practice, we are not using this approach just yet to escalate therapy. Time will tell how this all pans out. But I think what is even more interesting is the de-escalation question, and I think that is where tumor informed assays like Signatera and the data that our study generated can be applied. Actually, our plan is to generate some prospective data in the lobular breast cancer population, and I have an ongoing study to do that, to really be able to tease out the early ctDNA dynamics as patients first start on endocrine therapy. So, this is patients who are newly diagnosed, they are just starting on their first-line endocrine therapy, and measure, with sensitive assays, measure ctDNA dynamics in the first few months of therapy. In those patients who have a really robust response, that is where I think we can really think about de-escalation. In the patients whose ctDNA goes to undetectable after just a few weeks of therapy with just an endocrine agent, they might not even need a CDK4/6 inhibitor in their first-line treatment. So, that is an area where we are very interested in our group, and I know that other groups are looking at this too, to try to de-escalate therapy in patients who clear their ctDNA early on. Dr. Rafeh Naqash: Thank you so much. Well, lots of questions, but at the same time, progress comes through questions asked, and your project is one of those which is asking an interesting question in a rarer cancer and perhaps will lead to subsequent improvement in how we monitor these individuals and how we escalate or de-escalate therapy. Hopefully, we will get to see more of what you are working on in subsequent submissions to JCO Precision Oncology and perhaps talk more about it in a couple of years and see how the space and field is moving. Thanks again for sharing your insights. I do want to take one to two quick minutes talking about you as an investigator, Julia. If you could speak to your career pathway, your journey, the pathway to mentorship, the pathway to being a mentor, and how things have shaped for you in your personal professional growth. Dr. Julia Foldi: Sure, yeah, that is great. Thank you. So, I had a little bit of an unconventional path to clinical medicine. I actually thought I was going to be a basic scientist when I first started out. I got a PhD in Immunology right out of college and was studying not even anything cancer-related. I was studying macrophage signaling in inflammatory diseases, but I was in New York City. This was right around the time that the first checkpoint inhibitors were approved. Actually, some of my friends from my PhD program worked in Jim Allison's lab, who was the basic scientist responsible for ipilimumab. So, I got to kind of first-hand experience the excitement around bringing something from the lab into the clinic that actually changed really the course of oncology. And so, I got very excited about oncology and clinical medicine. So, I decided to kind of switch gears from there and I went back to medical school after finishing my PhD and got my MD at NYU. I knew I wanted to do oncology, so I did a research track residency and fellowship combined at Yale. I started working early on with the breast cancer team there. At the time, Lajos Pusztai was the head of translational research there at Yale, and I started working with him early in my residency and then through my fellowship. I worked on several trials with him, including a neoadjuvant checkpoint inhibitor trial in triple-negative breast cancer patients. During my last year in fellowship, I received a Conquer Cancer Young Investigator Award to study estrogen receptor heterogeneity using spatial transcriptomics in this subset of breast cancers that have intermediate estrogen receptor expression. From there, I joined the faculty at the University of Pittsburgh in 2022. So, I have been there about almost four years at this point. My interests really shifted slowly from triple-negative breast cancers towards ER-positive breast cancers. When I arrived in Pittsburgh, I started working very closely with some basic and translational researchers here who are very interested in estrogen signaling and mechanisms of resistance to endocrine therapy, and there is a large group here interested in lobular breast cancers. During my training, I was not super aware even that lobular breast cancer was a unique subtype of breast cancers, and that is, I think, changing a little bit. There is a lot more awareness in the breast cancer clinical and research community about ILC being a unique subtype, but it is not even really part of our training in fellowship, which we are trying to change. But I have become a lot more aware of this because of the research team here and through that, I have become really interested also on the clinical side. And so, we do have a Lobular Breast Cancer Research Center of Excellence here at the University of Pittsburgh and UPMC, and I am the leader on the clinical side. We have a really great team of basic and translational researchers looking at different aspects of lobular breast cancers, and some of the work that I am doing is related to this particular manuscript we discussed and the next steps, as I mentioned, a prospective study of early ctDNA dynamics in lobular patients. I also did some more clinical research work in collaboration with the NSABP looking at long-term outcomes of patients with lobular versus ductal breast cancers in some of their older trials. And so, that is, in a nutshell, a little bit about how I got here and how I became interested in ILC. Dr. Rafeh Naqash: Well, thank you for sharing those personal insights and personal journey. I am sure it will inspire other trainees, fellows, and perhaps junior faculty in trying to find their niche. The path, as you mentioned, is not always straight; it often tends to be convoluted. And then finding an area that you are interested in, taking things forward, and being persistent is often what matters. Dr. Julia Foldi: Thank you so much for having me. It was great. Dr. Rafeh Naqash: It was great chatting with you. And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Sean and Varn tackle the important question regarding the release of the much-vaunted 'Epstein Files': which ones of 'our faves' might be implicated? How do we avoid the 'socialism of fools' after this and Gaza? What does the Epstein story tell us about the rot at the heart of our ruling class? What do the files tell us about the absolute state of barbarism we currently live in and must find some way to work ourselves out of?N.B. at one point in the main episode Sean, in reference to diversity within Judaism, mentions the Satmar Hasidic community in NYC but neglects to mention why he brought it up which is because they one of the main sects that rejects Zionism on religious principle. To listen to the paywalled section where Sean and Varn elaborate more on these questions become a patron at www.patreon.com/thiswreckage and to watch the video recording of the whole thing become a patron of Varn at www.patreon.com/varnvlogThose interested in information about the Independent Labor Club can go to ILClabor.com and sign up.If you are in the Philadelphia area the ILC is having a first meetup for the Greater Philly chapter at Wissahickon Brewing Company on American Street Saturday, February 21st from 7pm to 8:30pm. For more info you can email ILCofPhilly at gmail dot com. Hope to see you there!Song: Gary Numan - This Wreckage

Listen and subscribe on Apple Podcasts | SpotifyHey all, Jason here.Alex Johnson, creator of the Fintech Takes newsletter, and I are happy to bring you the latest episode of our monthly podcast, Fintech Recap, where we unpack some of the biggest stories in fintech, banking, and crypto.In this episode, Alex and I had the chance to discuss:* The HBO drama “Industry” tackles banking and fintech and it gets dark (SPOILER WARNING)* Coinbase CEO Brian Armstrong rug pulls crypto market structure legislation* Are proposals for a 10% credit card cap and the re-emergence of the Credit Card Competition Act mere bargaining chips?* Affirm applies for an ILC charter* Capital One to acquire expense management and corp card startup Brex* And, as always, what Alex and I just can't let go of Get full access to Fintech Business Weekly at fintechbusinessweekly.substack.com/subscribe

Welcome back to Fintech Recap. I'm Alex Johnson, joined (as always) by my partner in recapping, Jason Mikula. Even if we aren't sailing to BaaS Island, the news keeps flooding in. We kick off with crypto market structure, which nearly cleared Congress before imploding. The Clarity Act would've locked in broad crypto rules, including limits on stablecoin yield. Banks had momentum to close a key Genius Act loophole (until Coinbase pulled support at the last second). The backlash was swift: other crypto firms were blindsided, lawmakers were furious, and Brian Armstrong ended up in Davos, facing off with Jamie Dimon (who, reportedly, told him to stop lying on TV).  Then it's onto banking charters. NewBank got conditional OCC approval. Ford, GM, and PayPal all made ILC moves. Affirm filed in Nevada, citing "flexibility and diversification," but this is about control. With rising scrutiny on partner banks and consent orders in the air, a charter gives Affirm cleaner economics and regulatory insulation. Like Square and LendingClub before it, the goal is clear: own the balance sheet, shift volume gradually, and keep options open. From there, Capital One's surprise acquisition of Brex for $5B. Most commentary focused on the exit. More interesting is what CapOne wants: startup spend volume and a wedge into high-growth business banking. Integration will take time, and as Ramp scales faster on a leaner model, pressure around ROI will be mounting. Plus, in our Can't Let It Go corner, we look at fintech's dumbest lawsuit: Prism v. TomoCredit. A fake cash flow underwriting product. A stolen trademark. Fabricated and backdated blog posts. An agreed settlement … that Tomo then refused to sign or memorialize. Meanwhile, the site still takes credit card details from consumers who can't unsubscribe. And somehow, it's still going! This episode is brought to you by Plaid.  Plaid helps lenders approve more creditworthy borrowers without taking on more risk, combining real-time cash flow data with behavioral insights. It's a fast, familiar experience people trust, and that actually converts. Learn more at www.plaid.com/ftt Sign up for Alex's Fintech Takes newsletter for the latest insightful analysis on fintech trends, along with a heaping pile of pop culture references and copious footnotes. Every Monday and Thursday: https://workweek.com/brand/fintech-takes/  And for more exclusive insider content, don't forget to check out my YouTube page. Follow Jason: Newsletter: https://fintechbusinessweekly.substack.com/ LinkedIn: https://www.linkedin.com/in/jasonmikula/   Follow Alex:  YouTube: https://www.youtube.com/channel/UCJgfH47QEwbQmkQlz1V9rQA/videos LinkedIn: https://www.linkedin.com/in/alexhjohnsonTwitter: https://www.twitter.com/AlexH_Johnson

In this episode of One Vision — FinTech Fuse, we took a deep dive into Walmart with Finovate's very own Julie Muhn. We started with Walmart's bold move to apply for an ILC charter in 2005, their foray into fintech with OnePay, and the wide array of services they now provide beyond retail. The conversation explored Walmart's integration of emerging technologies like AI and agentic commerce, as well as potential future developments and implications for traditional banks in retaining customer loyalty and trust in an increasingly digital financial landscape.00:00 Introduction and Guest Welcome01:07 Walmart's Evolution in Financial Services02:43 Walmart's Super App Ambitions03:41 Walmart's Diverse Service Offerings07:15 Challenges and Limitations of Walmart's App11:01 Agentic Commerce and Future Prospects18:31 Behavioral Data and Consumer Trust26:23 Conclusion and Final Thoughts

In this episode of One Vision — FinTech Fuse, we took a deep dive into Walmart with Finovate's very own Julie Muhn. We started with Walmart's bold move to apply for an ILC charter in 2005, their foray into fintech with OnePay, and the wide array of services they now provide beyond retail. The conversation explored Walmart's integration of emerging technologies like AI and agentic commerce, as well as potential future developments and implications for traditional banks in retaining customer loyalty and trust in an increasingly digital financial landscape.00:00 Introduction and Guest Welcome01:07 Walmart's Evolution in Financial Services02:43 Walmart's Super App Ambitions03:41 Walmart's Diverse Service Offerings07:15 Challenges and Limitations of Walmart's App11:01 Agentic Commerce and Future Prospects18:31 Behavioral Data and Consumer Trust26:23 Conclusion and Final Thoughts

Sean and Varn are back to talk current events, discuss theory and gripe about everyone and everything. On the tumbrils this week: artificial intelligence, the DSA, sovereign debt, multipolarity and how not to debate with Colin Drumm online. In the second half we talk about 'The Mamdani Moment', Varn's recent ascension to Chief Fly-in-the-Ointment in the DSA, the pre-political theories of the ILC and how the ruling class are dragging us all into the hellfire.For the full episode, and all past Divings into the Wreckage, support this show at http://patreon.com/thiswreckageSong: Gary Numan - This Wreckage

While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with a condition diagnosed in more than 40,000 Americans each year. Ohio State medical oncologist Arya Roy, MD, shares details about lobular breast cancer, also called invasive lobular carcinoma (ILC), including risks, symptoms and treatments.

Evropska unija želi z Aktom o umetni inteligenci spodbuditi zanesljiv in varen razvoj umetne inteligence, ki bo spoštoval temeljne človekove pravice, hkrati pa podpiral inovacije in zagotovil, da bo Evropa postala vodilna na tem področju. Nova zakonodaja naj bi v celoti začela veljati prihodnje leto. Kje je Slovenija na poti regulacije, kaj pomeni za regulacijo iniciativa »Stop-the-Clock«? Kateri sistemi umetne inteligence države že uporabljajo in zakaj bi potrebovali register umetne inteligence? Kako avtomatizacija vpliva na življenja ljudi in ali je visokotehnološki kapitalizem združljiv z demokracijo in varovanjem človekovih pravic? Pogovor je bil prvič objavljen v oddaji Intelekta. Gostje: Jasmina Ploštajner, Inštitut Danes je nov dan; Darja Petric Štrbenk, Ministrstvo za digitalno preobrazbo; dr. Ana Sobočan, Fakulteta za socialno delo Univerze v Ljubljani; dr. Blaž Vrečko Ilc, Fakulteta za družbene vede Univerze v Ljubljani. Avtorica oddaje Urška Henigman.

– ILC tem elevação em agosto.

The Jacksonville Jumbo Shrimp won the International League Championship after defeating the Scranton/Wilkes-Barre RailRaiders 2-1 in the ILC series. Next, they play for the AAA National Championship Saturday evening in Las Vegas. Harold Craw, Exeutive Vice President & General Manager of the Jumbo Shrimp, joins JMN to recap yesterday's game and promote this weekend's national title shot. It's one game, winner takes all, and you can hear it on ESPN690 or watch it on ESPN. First pitch is at 10:05pm EST!

Scott Kornberg, the Voice of the Jumbo Shrimp, joins JMN. The ILC series is split 1-1, and tonight's Game-3 vs. Scranton/Wilkes-Barre RailRaiders winners will be crowned the International League Champions. No pressure, right? But wait, there's more -- tonight's winners will face off against the Pacific Coast League champions in the AAA National Championship game Sept 27 in Las Vegas. The last time Jacksonville won the AAA championship was in 1968. The Jumbo Shrimp have a chance to make history for the Crustacean Nation!

Evropska unija želi z Aktom o umetni inteligenci spodbuditi zanesljiv in varen razvoj umetne inteligence, ki bo spoštoval temeljne človekove pravice, hkrati pa podpiral inovacije in zagotovil, da bo Evropa postala vodilna na tem področju. Nova zakonodaja naj bi v celoti začela veljati prihodnje leto. Kje je Slovenija na poti regulacije, kaj pomeni za regulacijo iniciativa »Stop-the-Clock«? Kateri sistemi umetne inteligence države že uporabljajo in zakaj bi potrebovali register umetne inteligence? Kako avtomatizacija vpliva na življenja ljudi in ali je visokotehnološki kapitalizem združljiv z demokracijo in varovanjem človekovih pravic? Odgovore smo iskali v tokratni oddaji Intelekta, kjer so se nam pridružili Jasmina Ploštajner z Inštituta Danes je nov dan, Darja Petric Štrbenk z Ministrstva za digitalno preobrazbo, izr. prof. dr. Ana Sobočan s Fakultete za socialno delo Univerze v Ljubljani in politolog doc. dr. Blaž Vrečko Ilc s Fakultete za družbene vede Univerze v Ljubljani.

In our 102nd episode, Mike Couillard and Jeremy Brewer discuss the how the trade deadline has impacted the fantasy futures of players dealt along with those stepping into new roles before diving into the standard injury and callup news and notes. Then we make select cards to enter the pod PC for the July Players of the Month.You can find us on bluesky at @cardscategories.bsky.social, @mcouill7.bsky.social, and @jbrewer17.bsky.social. Email the pod at cardscategories@gmail.com.We have Cards & Categories swag for purchase here!Links to things discussed in the pod:TRADE DEADLINE FALLOUTAll of the trades around the 2025 deadlineMLBTR's trade tracker by teamBiggest trades discussed:Carlos Correa shipped back to HoustonEugenio Suarez rejoins the M'sPadres acquire Mason Miller and JP Sears for package that includes Leo De VriesPadres also add Ramon Laureano and Ryan O'HearnRangers acquire Merrill KellyBlue Jays add Shane BieberMets trade for Cedric MullinsRisersJesus Sanchez & Jakob MarseeNew closers (Jose Ferrer, JoJo Romero, Randy Rodriguez, Dennis Santana)Kyle FinneganFreddy FerminKhal StephenDylan BeaversFallersEugenio SuarezOld closers (David Bednar, Camilo Doval, Ryan Helsley, Mason Miller)Incumbent closers losing role (Will Vest)Former starting-ish bats heading to part-time roles (Willi Castro, Jose Caballero, Will Wagner)Gavin SheetsNews & Notes Discussion (1:02:45)A tibia contusion shelves Jacob MisiorowskiJackson Chourio heads to IL with hamstring strainJonathan Aranda breaks wrist on collision in the field, possibly done for seasonGrayson Rodriguez undergoing elbow debridement surgeryAustin Riley returns to IL with same abdominal injury from last monthMichael Soroka leaves first Cubs start with bum shoulder, lands on ILRight ankle sprain sends Tommy Edman to ILC.J. Kayfus promoted to the big leaguesContentious meeting in Phillies clubhouse between players and Rob Manfred sets stage for labor negotiationsTopps officially will allow Chrome Update cards for the MVP Buyback programUpcoming baseball card release schedule:8/6: 2025 Topps Archives Signature Series Active Players Edition8/12: 2025 Topps Finest8/13: 2025 Panini Prizm8/15: 2025 Panini Boys Of Summer8/29: 2025 Panini ImpeccableCARDS DISCUSSION (1:44:10)July POTM PC (link to Razzball post)MLB article on July's winnersC&C Pod PC listNick KurtzJ: 2025 Choice Las Vegas AviatorsM: 2025 Topps Now #464Kyle StowersJ: 2025 Topps Series 2 Golden Mirror Image Variation #399 M: 2025 Topps Now #ODB14 Road To Opening Day BonusNathan EovaldiJ: 2024 Topps Chrome Sapphire Red /5 #258 M: 2011 Bowman Chrome #BCP165 first autoPaul SkenesJ: 2023 Bowman Draft Mood Ring #MR-1M: 2024 Bowman Spotlights #BS1 gold refractor #/50Isaac CollinsJ: 2025 Topps Chrome #92 Frozen Fractor -1/0M: 2021 Choice Spokane Indians Isaac Collins

– ILC registra inflação em junho.

In this episode, hosts welcome back Jeremy Wells, author, brand strategist, and co-owner of The Ozarker Lodge and the newly reimagined Parker Hotel in Colorado.Jeremy shares what it's been like since opening The Ozarker Lodge—lessons learned, community wins, and how indie spirit fuels every project. He also dives into his second book, Indie Hotels, a heartfelt blend of memoir and hospitality insights that's already making waves across the industry.Joining the conversation is Stephen Chan, co-founder of Eagle Point Hotel Partners, the investment group behind both The Ozarker Lodge and Parker Hotel. Stephen gives us a behind-the-scenes look at the $24M Parker property acquisition and talks trends in boutique hotel investing, including their new stealth-mode venture, Arbus Hospitality.We explore:How Jeremy and Stephen approach branding, design, and repositioningThe importance of community integration for boutique propertiesLessons from growing a hotel brand post-COVIDWhy the independent hotel scene continues to thriveThe future of ILC and its mission to inspire collaborationWatch the FULL EPISODE on YouTube: https://youtu.be/KuAExHR7BHAJoin the conversation on today's episode on The Modern Hotelier LinkedIn pageThe Modern Hotelier is produced, edited, and published by Make More MediaLinks:Jeremy WellsJeremy on LinkedIn: https://www.linkedin.com/in/wellsjeremy/ Longitude°: https://longitudedesign.com/INDIE HOTEL: Why Hoteliers Are Breaking Free from Chains and Choosing Independence Book: https://www.amazon.com/INDIE-HOTEL-Hoteliers-Breaking-Independence/dp/B0CHL4713KStephen ChanStephen on LinkedIn: https://www.linkedin.com/in/stephen-chan-1b70142b/Eagle Point Hotel Partners: https://www.eaglepointhotels.com/For full show notes head to: https://themodernhotelier.com/episode/189Follow on LinkedIn: https://www.linkedin.com/company/the-...Connect with Steve and David:Steve: https://www.linkedin.com/in/%F0%9F%8E...David: https://www.linkedin.com/in/david-mil.

In this episode, hosts David Millili and Steve Carran sit down with the dynamic Meg Gutowski, Executive Director of the Independent Lodging Congress (ILC), live from ILC CONfab in Chicago. Meg shares her unconventional journey from catering weddings to leading one of the most vibrant communities in independent hospitality.She opens up about what makes ILC truly special—from building real partnerships with host properties to curating events where business gets done, but fun is never far behind. From rooftop cocktails to Miami shenanigans, you'll hear how Meg and the ILC team are redefining what it means to connect in this industry.Whether you're an independent hotelier, event producer, or just love hospitality done differently, this episode is packed with insight, laughs, and a whole lot of heart.Watch the FULL EPISODE on YouTube: https://youtu.be/DmZ_h4o24KMJoin the conversation on today's episode on The Modern Hotelier LinkedIn pageThe Modern Hotelier is produced, edited, and published by Make More MediaLinks:Meg on LinkedIn: https://www.linkedin.com/in/meg-gutowski-09b33972/ILC: https://ilcongress.com/For full show notes head to: https://themodernhotelier.com/episode/188Follow on LinkedIn: https://www.linkedin.com/company/the-...Connect with Steve and David:Steve: https://www.linkedin.com/in/%F0%9F%8E...David: https://www.linkedin.com/in/david-mil.

I was joined this week by Murtaza Ali, CEO & Co-Founder of Symphony (YC F24), for a conversation about how he's tackling some of the biggest challenges in the insurance industry with cutting-edge voice AI — without losing sight of the human touch.A bit of context: Murtaza's journey insurtech journey started at McKinsey before joining Tractable to build out their platform. He's seen firsthand how AI can transform industries — but also where it can fall short without humanity in the loop. That insight became the driving force behind Symphony AI.What we covered in this episode:

Michael Starr (New York Post) kicks off the show to talk about his new book Nothin' Comes Easy: The Life of Rodney Dangerfield. Starr has also written biographies of Don Rickles, Bob Newhart, Bobby Darin, Raymond Burr, William Shatner, Redd Foxx and Ringo Starr among others. Randy Wenger, Chief Counsel with Independence Law Center, gives insight into the U.S. Supreme Court ruling on the Medina v Planned Parenthood South Atlantic case as well as the work of ILC. Ziggy Marley also jumps in to share about his new children's book Pajammin' (a play on the title of his father Bob Marley's song "Jammin'"), his September concerts in Pennsylvania & Maryland and his U.R.G.E. Foundation. Theodora DeMoss, the youngest of the DeMoss children, helps put the finishing touches on the show by assisting dear ol' dad with Now THAT'S Punny!See omnystudio.com/listener for privacy information.

Il a découvert la voile à l'adolescence, entre Toulouse et Gruissan, dans une famille baignée par l'aéronautique - loin des capitales de la régate. C'est aux côtés de son père Ortwin, pionnier d'Airbus, que Stephan Kandler fait ses premières armes, en croisière puis en course, avant de professionnaliser cette passion au sein de K Yachting. Très actif dans les années 1990 sur les circuits ILC 40, Mumm 30 ou Corel 45, il construit des programmes ambitieux en équipage, repère de futurs grands noms (Juan Kouyoumdjian, Guillaume Verdier) et attire les meilleurs navigateurs français des circuits inshore.En 2001, à 30 ans, il se lance dans l'aventure Coupe de l'America avec la création de K-Challenge. Six ans plus tard, son équipe représente la France à Valence sous le nom Areva Challenge, après avoir frôlé la banqueroute. Le défi français se classe sixième de la Louis Vuitton Cup et parvient à rivaliser avec des écuries bien mieux dotées. L'avenir s'annonce prometteur - Stephan Kandler assure avoir alors réuni un budget de 60 millions d'euros grâce à un mécène et un partenaire -, mais le conflit judiciaire entre Oracle et Alinghi gèle tout projet de suite et tout s'effondre.Il rebondit en TP52 avec All4One durant trois saisons, sans parvenir à revenir dans la Coupe et prend ce qu'il pense être sa retraite de la voile pour se tourner vers les vignes pendant près de huit ans. Kandler revient à la voile en 2021, motivé par l'évolution technologique des supports et l'essor de SailGP. Il s'associe à Bruno Dubois et relance K-Challenge, avec l'objectif de concourir à la 37e America's Cup à Barcelone. C'est le groupe Accor, via sa marque Orient Express, qui relance définitivement la machine fin 2022. En deux ans à peine, un AC75 est construit chez Multiplast, issu du design package des Kiwis et l'équipe s'aligne dans les délais.Sur le plan sportif, Quentin Delapierre et les siens créent la surprise en remportant la première régate officielle à Villanova en AC40. Mais le manque d'entraînement sur l'AC75 et l'inexpérience de ce type de support pénalisent la suite du parcours. Malgré une victoire symbolique contre Alinghi, le défi tricolore ne se qualifie pas pour les demi-finales. Une "déception" sportive, Kandler ne s'en cache pas.Aujourd'hui, K-Challenge poursuit l'aventure à travers sa présence en SailGP, où elle aligne le même équipage qu'en America's Cup. L'équipe s'est ancrée à Lorient, via des activités technologiques (hydrogène, software embarqué, simulateur) qui nourrissent à la fois la performance et des débouchés industriels.Alors que la 38e édition de la Coupe se profile à Naples en 2027, Stéphane Kandler affiche son ambition : capitaliser sur l'expérience de Barcelone pour construire une équipe encore plus compétitive. La France a (re)pris pied dans la Coupe. Il reste désormais à s'y imposer. Et Stephan Kandler en est sûr : jamais cela n'a été aussi possible.Diffusé le 30 Mai 2025Générique : In Closing – Days PastPost-production : Grégoire LevillainHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

In this episode of FinTech Layer Cake, host Reggie Young speaks with Michele Alt, Co-Founder of Klaros Group, about new opportunities in fintech bank charters.They unpack the recent SmartBiz approval, what it signals for the industry, and the realities of the charter process—from regulatory hurdles to risk management. Michele also shares why now might be the best time in years to act—and why ILC charters could be the next big thing.If you're thinking about chartering, partnering, or future-proofing your fintech, this episode is a must-listen.

When it comes to fintechs getting bank charters we are entering a golden age. With zero fintech-oriented bank applications approved in the Biden administration we already have several fintechs with shiny new bank charters just a few months into the new administration. So, if you are a fintech and are thinking about bank charters now is the time.To break all this down, I was delighted to chat recently with Michele Alt, Co-Founder and Managing Director at Klaros Group. She was last on the show in 2021 and certainly a lot has changed since then. Michele takes us through the different types of charters and explains the different options for fintech companies seeking charters.On this podcast you will learn:The fundamental change in attitude for bank charters with the new administration in DC.The two paths that fintechs can take to get a bank charter.The pros and cons for each of these paths.Michele's thoughts on the SmartBiz acquisition of Centrust Bank.Why she thinks the timelines for bank acquisitions will be shorter from now on.The difference between an ILC charter and a regular bank charter.Why most ILC banks are located in Utah.Why some of the big names in fintech are applying for the MALPB charter in Georgia.Why Wyoming created the SPDI charter.How the Federal Reserve is reacting to this change in the new bank formation environment.Why some of the crypto companies are looking for federal bank charters.Michele's perspective on the big tech companies getting bank charters.What she would say if Amazon came calling looking to explore an ILC charter.What the fintech banking landscape might look like at the end of the Trump administration.Connect with Fintech One-on-One: Tweet me @PeterRenton Connect with me on LinkedIn Find previous Fintech One-on-One episodes

Join us for an episode recorded in August 2024, with Huw Llewellyn, the former Director of the Codification Division of the United Nations Office of Legal Affairs and former Secretary to the International Law Commission (ILC), in a conversation about the evolution of international law. We cover the history of the ILC, its role in the evolution of international law, and its relationship with the UN Sixth Committee. Huw shares insights from his 42-year career, revealing the Commission's approach to codification and progressive development of the law. The episode also explores the historical milestones that shaped international law, from the Peace of Westphalia in 1648 to the League of Nations. Huw talks about how stability and change in international relations is reflected in the work of the ILC, tells us more about the Commission's achievements over 75 years, and new areas of work on the agenda including the topic of sea level rise. We conclude with a personal glimpse into Huw's retirement plans and his recommendations for crime thriller enthusiasts (Lee Child and Martin Walker)! Resources: Ask a Librarian! International Law Commission: https://legal.un.org/ilc/ Resource guide: https://libraryresources.unog.ch/legal/legal/ILC   Where to listen to this episode  Apple podcasts:  https://podcasts.apple.com/us/podcast/the-next-page/id1469021154 Spotify: https://open.spotify.com/show/10fp8ROoVdve0el88KyFLy YouTube: https://youtu.be/FZX3y3SADV4 Content    Guest: Huw Llewellyn Host: Amy Smith, UN Library & Archives Geneva Production and editing: Amy Smith Recorded & produced at the United Nations Library & Archives Geneva 

Rodrigo Álvarez conversó con el senador José Miguel Insulza y también estuvo con Los Infiltrados Gloria Faúndez con el despeje de la carrera oficialista a La Moneda y Mariana Marusic con por qué ILC es la acción que más renta en 2025.

This is a recording of the ILC's fourth public assembly at Woodbine Space in Queens on March 29th, 2025 featuring Cyrus Cappo of John Jay College CUNY, Daniel Jacobs of Sublation/Platypus Affiliated and Ryan Castello of the Maoist Communists Union.For more info on the Independent Labor Club of North America-including upcoming events, how to join, how to start a chapter, etc-visit the website at https://ilclabor.com/Song: Dodos - Trades and Tariffs

Is there power behind organized chaos? Today, Dan Ryan engages with Meg Gutowski, Vice President of the Independent Lodging Congress (ILC). They discuss the essence of hospitality, the role of ILC in fostering connections among industry professionals, and the unique blend of events hosted by ILC that emphasize genuine human interactions over transactional relationships. Meg shares insights from her extensive experience in the hospitality industry, including planning initiatives, organizing events, and the importance of creating meaningful experiences for attendees. They also delve into personal anecdotes and the intricacies of balancing organized chaos in event planning. The episode emphasizes the transformative power of hospitality and the vital role of independent lodging in the industry.Takeaways: Emphasize the mission of hospitality to care for people on their journeys. This core purpose should guide all actions and decisions.Strive to create experiences that blend the unexpected with fulfilling guest expectations, making their stays magical but ensuring they feel taken care of.Use unique and less formalized settings, like walk-and-talks, immersive experiences, and local tours, to encourage organic interactions and deeper connections among attendees.Building authentic relationships is crucial. In the hospitality industry, human connection and genuine interactions can set your business apart.Engage with local businesses and community members to enhance the collective experience for visitors.Choose venues and spaces that are comfortable and stimulating for guests, considering their comfort during events and interactions.Quote of the Show:“ Trying to figure out the right combination so that it feels very magical, but also you feel like you're taken care of. That's how hospitality has been running through my brain.” - Meg GutowskiLinks:LinkedIn: https://www.linkedin.com/in/meg-gutowski-09b33972/ Website: https://ilcongress.com/ Shout Outs:0:48 - Corinthian Yacht Club https://www.corinthianyc.org/ 1:47 - Bashar Wali https://www.linkedin.com/in/basharwali/ 5:45 - Andrew Benioff https://www.linkedin.com/in/llenrockgroupbenioff/ 7:18 - Cavallo Point Lodge https://www.cavallopoint.com/ 16:50 - Elyse Kirby https://www.linkedin.com/in/jelysekirby/ 17:25 - Sage Hotels https://sagehospitalitygroup.com/ 21:57 - Marquise Stilwell https://www.linkedin.com/in/quise/ 24:01 - Morris Adjmi Architects https://ma.com/ 24:05 - MethodCo https://www.methodco.com/ 25:07 - Alexis Lanman https://www.linkedin.com/in/alexis-lanman-b0b39487/ 25:08 - Jen Parks https://www.linkedin.com/in/jenniferfigariparks/ 32:35 - Highgate https://www.highgate.com/ 38:38 - Paul Tamburello https://www.linkedin.com/in/paul-tamburello-80638512/ 39:16 - Little Man Ice Cream https://www.littlemanicecream.com/ 46:27 - Amy Michaelson Kelly https://www.linkedin.com/in/amy-michaelson-kelly-a547a717/ 46:30 - Lark https://www.larkhotels.com/ 46:41 - Shelton Steele https://www.linkedin.com/in/shelton-steele-39521566/ 46:42 - Wrong Way Campground https://www.wrongwaycampground.com/ 

Nine years with no evidence of disease—yet Megan-Claire Chase's cancer journey isn't over. As she once fought cancer alongside her mother, she now faces something even harder: losing her. In this episode, Megan-Claire shares a deeply vulnerable side—a daughter losing her mother. Facing your own mortality is one thing, but facing the mortality of your loved ones—friends, family, fellow cancer patients, and survivors—and the hole they leave behind is something entirely different. Key Highlights: Witnessing her mother's cancer progression brings anticipatory grief, yet despite that grief, Megan strives to learn as much about her mother as possible, including fond memories from her childhood. Despite the anticipatory grief, Megan and her mother engage in a bonding exercise using question cards, and she records their conversations. One of the most meaningful things she learned was that her mother reflects on her life with joy—ultimately, the greatest goal is to leave this world happy. Facing your own mortality can unearth many emotions: the need to be confident and not tolerate disrespect, the desire to live life on your own terms and to the fullest, yet also a deep sense of loneliness and isolation. About our guest: Check out the first episode Megan-Claire Chase appeared in here.  Megan-Claire Chase, also known as Warrior Megsie, is the Breast Cancer Program Director and host of the Our BC Life podcast at SHARE Cancer Support. As an invasive lobular carcinoma (ILC) breast cancer survivor and passionate patient advocate based in Atlanta, GA, Megan-Claire is a dedicated champion for the needs of breast cancer patients, particularly in addressing the disparities faced by minoritized communities and those in the adolescent and young adult (AYA) communities. In addition to her pivotal role at SHARE, she serves on Bayer Oncology's Digital Patient Council, is a patient advocate for the Oncology Data Advisor Editorial Board, and recently joined the Worth the Wait Charity advisory board. She also contributes as a writer and advisory board member for Patient Power, amplifying the voices of breast cancer patients. Megan-Claire's advocacy efforts include participating as a panelist on Leveraging Technology to Support Patient-Centered Multidisciplinary Oncologic Care at the 2024 ASCO Quality Care Symposium, co-authoring a podcast and infographic on genetic testing in metastatic breast cancer, collaborating with Pfizer on the Action Guide to Disrupt Inequitable Health Outcomes, and sharing her personal journey on PBS's Beyond Cancer through Stories from the Stage. Her work has been spotlighted in notable publications like The New York Times, People Magazine, Cancer Health, Cancer Today, and CURE Magazine. Beyond her cancer advocacy, Megan-Claire is a versatile voiceover actor, a dedicated social justice activist, and a proud cat mom to Phoebe. Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only.  This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Looking for tools to help you take control of your cancer experience? Check out My Cancer GPS™, a step-by-step map that guides you through the entire cancer experience.

In this episode, the team reflects on an exceptional year for the Modern Hotelier podcast, which gained recognition as a top hospitality podcast and more than doubled its follower base across LinkedIn, YouTube, and Instagram.The hosts reminisce about attending key industry events like HITEC, ILC in Sausalito, and the Hospitality Show, sharing their favorite moments and interviews. They also discuss the biggest lessons learned over the year and express gratitude to their guests, sponsors, and followers, teasing exciting announcements for 2025.Happy Holidays and Merry Christmas from the Modern Hotelier team!Join the conversation on today's episode on The Modern Hotelier LinkedIn pageThe Modern Hotelier is produced, edited, and published by Make More MediaLinks:For full show notes head to: https://themodernhotelier.com/episode/126Follow on LinkedIn: https://www.linkedin.com/company/the-...Connect with Steve and David:Steve: https://www.linkedin.com/in/%F0%9F%8E...David: https://www.linkedin.com/in/david-mil...

Dr. Linda Chu is joined by Dr. Matthew Covington and Dr. Regina Rosenthal to discuss the challenges in diagnosing and treating invasive lobular carcinoma (ILC) of the breast. They explore imaging difficulties, unique metastatic patterns, and strategies for improving detection and patient care. Sponsored by GE HealthCare.

On November 9th, 2024 the Independent Labor Club of NY hosted a panel at Woodbine in Ridgewood, Queens. Sean moderated this discussion between:Aaron Lelonde of the International Longshoremen's AssociationSou Mi of WGA-East and Left VoiceGregory Butler of Int'l Union of Operating Engineers and Gangbox NewsEllie Pfeffer of Maoist Communist Union, formerly of Amazonians UnitedWhat accounts for the realignment seen in 2024? Did large swathes of workers (including Black and Hispanic) vote Trump solely from racism and misogyny? What was the role of organized labor in the recent election? What effects might the results of the election have on the prospects for organizing labor in the future?If you like what you hear, support our podcast and access great bonus content: www.patreon.com/theantifadaIf you're interested in joining the ILC, we have chapters across the country and in Australia: https://ilclabor.com/The event was held @woodbine.nyc in Ridgewood, Queens Saturday November 9th. Contribute to Woodbine's Fall Fundraiser drive.Song - Capital STEEZ x Joey Bada$$ - Survival Tactics

Independent hotels are the creative spark for the Hospitality Industry. So, what's the current state of the Independent Hospitality sector?In this episode, David and Steve head to the Independent Lodging Congress in Sausalito, CA to talk about the latest insights and challenges happening in the Independent hotel space. On this episode we hear from Andrew Benioff, the Founder and Chairman of ILC, Peter Heinemann, Co-founder and Managing Director of Passport Resorts, and Lindsey Ueberroth, the CEO of Preferred Hotels & Resorts. Key Topics:How Independents are leading the way in creativityWhy this is the Golden Age of HospitalityWhat big brands buying up independents means for Independent hospitality as a wholeThe challenges and opportunities facing the independent hotel space currentlySponsor spot:The Modern Hotelier is the official podcast of the Independent Lodging CongressJoin the conversation on today's episode on The Modern Hotelier LinkedIn pageThe Modern Hotelier is produced, edited, and published by Make More MediaLinks:Andrew Benioff: https://www.linkedin.com/in/llenrockgroupbenioff/Peter Heinemann: https://www.linkedin.com/in/peter-heinemann-9662035/Lindsey Ueberroth: https://www.linkedin.com/in/lindseyueberroth/ILC | Independent Lodging Congress: https://ilcongress.com/Passport Resorts: https://passportresorts.com/Preferred Hotels & Resorts: https://preferredhotels.com/For full show notes head to: https://themodernhotelier.com/episode/102Follow on LinkedIn: https://www.linkedin.com/company/the-...Connect with Steve and David:Steve: https://www.linkedin.com/in/%F0%9F%8E...David: https://www.linkedin.com/in/david-mil...

Independent hotels are the creative spark for the Hospitality Industry. So, what's the current state of the Independent Hospitality sector?In this episode, David and Steve head to the Independent Lodging Congress in Sausalito, CA to talk about the latest insights and challenges happening in the Independent hotel space. On this episode, we hear from Dan Jacobs, the Chef/Owner, of award-winning restaurants, Dandan & EsterEv, in Milwaukee, Gaurav (GB) Sharma, Founder of MOSAIC, Audrey Yates, the VP of Hotel Partnerships at Stash Hotel Rewards, and Brian Polster the Creative Director at THREE SIXTY.Key Topics:What is the company's role in the hospitality industryHow does ILC compare to other industry eventsWhat makes ILC unique in terms of networking and atmosphereHow are businesses preparing for upcoming industry changesThe Industry Innovation The Modern Hotelier is the official podcast of the Independent Lodging CongressJoin the conversation on today's episode on The Modern Hotelier LinkedIn pageThe Modern Hotelier is produced, edited, and published by Make More MediaLinks:Dan Jacobs: https://www.linkedin.com/in/dan-jacobs-ba774327b/Gaurav Sharma: https://www.linkedin.com/in/gbnewyork/Audrey Yates: https://www.linkedin.com/in/audrey-yates-0b5331b4/Brian Polster: https://www.linkedin.com/in/brianpolster/  EsterEv | Milwaukee Private Dining Restaurant: https://chefdanjacobs.com/MOSAIC: https://mosaicinabox.com/Stash Hotel Rewards: https://www.stashrewards.com/THREE SIXTY: https://threesixtymke.com/For full show notes head to: https://themodernhotelier.com/episode/103Follow on LinkedIn: https://www.linkedin.com/company/the-...Connect with Steve and David:Steve: https://www.linkedin.com/in/%F0%9F%8E...David: https://www.linkedin.com/in/david-mil...

In this episode of the Patient From Hell, Samira sits down with Megan-Claire Chase, known in the cancer community as "Warrior Megsy." Megan-Claire shares her deeply personal experience of navigating breast cancer and its aftermath. From managing the physical and emotional toll of treatment to finding new ways to regain a sense of self, Megan-Claire offers a powerful account of resilience, self-advocacy, and the importance of asking for help. Her humor, storytelling skills, and openness bring a refreshing perspective on survivorship, making this an inspiring conversation for anyone facing adversity. Key Highlights: 1. Self-advocacy is critical in healthcare, and sometimes, switching doctors is necessary to ensure your voice is heard. 2. The emotional impact of cancer extends beyond treatment, often manifesting in long-term physical pain and identity challenges. 3. Asking for help isn't a sign of weakness—it's a vital step in dealing with the overwhelming aspects of cancer. About our guest: Megan-Claire Chase, also known as Warrior Megsie, is the Breast Cancer Program Director and host of the Our BC Life podcast at SHARE Cancer Support. As an invasive lobular carcinoma (ILC) breast cancer survivor and passionate patient advocate based in Atlanta, GA, Megan-Claire is a dedicated champion for the needs of breast cancer patients, particularly in addressing the disparities faced by minoritized communities and those in the adolescent and young adult (AYA) communities. In addition to her pivotal role at SHARE, she serves on Bayer Oncology's Digital Patient Council, is a patient advocate for the Oncology Data Advisor Editorial Board, and recently joined the Worth the Wait Charity advisory board. She also contributes as a writer and advisory board member for Patient Power, amplifying the voices of breast cancer patients. Megan-Claire's advocacy efforts include participating as a panelist on Leveraging Technology to Support Patient-Centered Multidisciplinary Oncologic Care at the 2024 ASCO Quality Care Symposium, co-authoring a podcast and infographic on genetic testing in metastatic breast cancer, collaborating with Pfizer on the Action Guide to Disrupt Inequitable Health Outcomes, and sharing her personal journey on PBS's Beyond Cancer through Stories from the Stage. Her work has been spotlighted in notable publications like The New York Times, People Magazine, Cancer Health, Cancer Today, and CURE Magazine. Beyond her cancer advocacy, Megan-Claire is a versatile voiceover actor, a dedicated social justice activist, and a proud cat mom to Phoebe. My Cancer GPS™ is coming! Step-by-step subway maps that guide you through the entire cancer experience. Learn more here!⁠ Key Moment: 21 minutes: “Something that people outside of Cancerland may not fully understand is the side effects from the toxic treatments, the side effects from multiple surgeries, the pain that some get fades, they heal, but for others, like moi, I really got the motherload of permanent damage, permanent side effects, effects that happen like a year, two years post cancer. And so I, as I'm talking to you right now, I am in pain. And I often have people say, ‘you don't look like you're in pain.' And I'm like, look, it's not Halloween yet. I don't want to scare you. If I looked how I truly, truly felt on the daily, you would think you're in a scary movie. And so, dealing with multiple types of pain, chronic pain, is something I never, ever thought would be part of my cancer experience." Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only.  This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

This podcast was originally a YouTube video, you can watch that video here: https://youtu.be/9mFgp2gE4PMYou don't need to work longer, you just need a better plan. Schedule a consultation with Charles to tailor a plan that suits your unique financial goals: https://calendly.com/charlesdzama/dzamatalk-complimentary-15-min-phone-callLINK TO OPM: https://www.opm.gov/retirement-center/fers-information/survivors"Understanding the FERS Basic Employee Death Benefit (BEDB): A Crucial Safety Net for Federal|Employees"Chapters:0:01 - Introduction to the Episode0:25 - Why talk about it? - Misconceptions about BEDB0:40 - Overview of FERS and BEDB1:20 - Real-life Impact: A Family's Story|2:35 - How BEDB Works: Detailed Explanation3:24 - Will I eat up my Sick and Annual Leave Importance of Sick and Annual Leave4:33 - Strategic Use of Leave for Health Issues5:15 - Financial Details of BEDB5:47 - Closing Remarks and How to Get More InformationConnect with CD Financial for More Insights:  Twitter: /CDFinancial_LLC  Instagram: /CDfinancial. Ilc  Facebook: /CDFinancialLLCl  LinkedIn: /cd-financial-Ilc |Visit our Website https://cdfinancial.org/Subscribe and Stay Updated:Don't miss out on crucial advice for your financial journey. Subscribe now for weekly insights and strategies to secure your retirement.Get More from CD Financial:Looking for personalized advice? Schedule a consultation with Charles to tailor a plan that suits your unique financial situation. https://calendly.com/charlesdzama/dzamatalk-complimentary-15-min-phone-calli#RetirementPlanning #TSP #401K #FinancialAdvice #InvestmentStrategySupport the Show.

Monday rolls around and it's time for another episode on The Leadership In Insurance Podcast

Audio from ILC's first Independent Labor Assembly July 7th, 2024 assembly at Talon Bar in Brooklyn with guest Gregory ButlerFor the full episode, Discord access, and all our bonus content, support the show at http:///patreon.com/theantifadaThe Independent Labor Club is an organization that seeks to bring workers together from all over to build bonds of free association and strengthen the power of labor. Our guest speaker Gregory A. Butler is a lifelong New Yorker as well as a carpenter in local 608, United Brotherhood of Carpenters & Joiners of America. With decades of experience in the trades, he focuses on the history of working class struggle and union organizing in New York. He is the author of Disunited Brotherhood: Race, Racketeering and the Fall of the New York Construction Unions and is owner and moderator of Gangbox: Construction Workers News Service on the yahoo groups network.Song: Johnny Cash - One Piece At A Time

Our guest this week is someone who is committed to elevating communities and creating wealth through hospitality ownership and leadership. Please welcome to the show, Founder of Hospitality Hued, Ashli Johnson!Ashli sits down with Host Dan Ryan to discuss the ways the hospitality industry can be more accommodating of Black and Brown professionals. Ashli shares her motivations for founding Hospitality Hued, the importance of early professional development, and how to instill a sense of ownership in employees.Takeaways: While hospitality is ultimately a business of service, it is rapidly evolving to better address DEI issues across employment, supplier diversity, and leadership. To remain impactful, those in the industry must actively engage in these conversations.Conferences and networking are a crucial part of success in the hospitality industry, yet many Black and Brown leaders find themselves “under conferenced”. To combat this, HUED was created to lower barriers to these opportunities for Black and Brown leaders.Leverage alumni networks to bridge the gap between academic learning and practical career development. Don't overlook the importance of having a strategic approach when pursuing career goals to avoid potential disadvantages and seize growth opportunities.To motivate teams to think like owners, consider actually giving them ownership stakes, as it fundamentally changes their understanding and investment in the business. Implementing an equity share model can drive engagement from general managers.In hospitality, it's crucial to understand how positive guest experiences impact the business's overall success and competitive position. Recognizing the connection between guest satisfaction and business metrics such as rates, market competition, and capital expenditures is essential for professional growth and effective management.Aspiring hotel or restaurant owners should carefully consider their financial and personal responsibilities before pursuing ownership. Instead of direct ownership, roles such as investor or franchisee have lower capital requirements and barriers to entry.Surround yourself with like-minded individuals who want to master the business, and ensure that your leadership is aware of your interests to help you move towards your desired career path.Quote of the Show:“Your fortune is found in the follow up.” - Ashli JohnsonLinks:LinkedIn: https://www.linkedin.com/in/itsashlijohnson/ Website: https://www.hospitalityhued.com/ Shout Outs:2:12 - HD Vegas: https://hdexpo.hospitalitydesign.com/ 2:47 - Howard University: https://howard.edu/ 2:50 - Marriott-Sorenson Center for Hospitality Leadership: https://business.howard.edu/hospitality-leadership 44:52 - John Fareed: https://www.linkedin.com/in/johnfareed/ 45:06 - From Invisible to Icon: How to Become a Known Expert in Your Industry: https://a.co/d/03AZNsoL 45:41 - Julien Saunders: https://www.linkedin.com/in/juliensaunders/ 45:42 - Kiersten Saunders45:47 - Rich and Regular: https://richandregular.com/ 46:36 - Thomas Penny III: https://www.linkedin.com/in/thomas-penny-iii-1aa40915/ 46:42 - Damon Lawrence: https://www.linkedin.com/in/hauspitality/overlay/about-this-profile/ 46:45 - Jason Bass: https://www.linkedin.com/in/jasoncbass/ 47:01 - ILC: https://ilcongress.com/ 47:15 - Kendra Plummer: https://www.linkedin.com/in/kendraplummer/ 47:37 - Bashar Wali: https://www.linkedin.com/in/basharwali/ 47:56 - Lauren A. K. Darnell: https://www.linkedin.com/in/laurenadarnell/ Ways to Tune In: Spotify: https://open.spotify.com/show/0A2XOJvb6mGqEPYJ5bilPXApple Podcasts: https://podcasts.apple.com/us/podcast/defining-hospitality-podcast/id1573596386Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly93d3cuZGVmaW5pbmdob3NwaXRhbGl0eS5saXZlL2ZlZWQueG1sAmazon Music: ​​https://music.amazon.com/podcasts/8c904932-90fa-41c3-813e-1cb8f3c42419

Following a brilliant event at I Love Claims last week, we are excited to release our 1st episode covering the the behind the scens on The Leadership In Insurance Podcast today

Welcome back to another episode of Apostolic Sunday School podcast! In this episode, Danny and Phillip dive into the latest happenings at ILC and share their insights. The highlight of this episode is the...

In this episode we're learning from Meg Gutowski, the Events and Operations Senior Director at the Independent Lodging Congress (ILC). With a wealth of experience in producing top-tier events, Meg shares her insights into what it takes to create gatherings that are not only memorable but also foster genuine connections.Listeners will learn about:The Creative Process: Discover how Meg and her team at ILC blend meticulous planning with spontaneity to curate unique event experiences.Venue Selection: Understand the importance of choosing the right venue and how it can significantly impact the success of an event.Engaging Formats: Explore the various interactive and engaging formats used by ILC to keep attendees interested and involved, from fashion contests to hot wing challenges.Fostering Relaxation: Gain insights into how ILC encourages a relaxed atmosphere that allows industry executives to let their guard down and truly engage.Collaboration and Partnerships: Learn about the collaborative efforts with advisory boards, local businesses, and venues that contribute to the richness of ILC events.Upcoming Events: Get a sneak peek into the exciting upcoming events planned by ILC, including the venues and cities they will be showcasing. Music by Clay Bassford of Bespoke Sound: Music Identity Design for Hospitality Brands

In the latest episode of Investigating Breast Cancer, Dr. Adrian Lee discusses collaboration, strategies to improve treatment for ILC, and more. A BCRF investigator since 2013, he is the Pittsburgh Foundation chair and director of the Institute for Precision Medicine at the University of Pittsburgh and UPMC

Ripped from the pages of the popular Wildfire Magazine anthology, Igniting the Fire Within, we've curated this special mini podcast for you. Each Friday, hear a new bite-sized episode. Featuring “just the stories” from the book read by the authors. Think of this as your dynamic audiobook version of Igniting the Fire Within. Enjoy! This episode features April Stearns reading Leslie's essay “Love. At Last.” Leslie Martin. Elementary School Teacher, Spin Instructor, Mom. Diagnosed at 44. ILC, Stage II, Triple Positive. Huntington Beach, CA.This episode contains the subject matter of childhood sexual abuse.Buy the Wildfire book Igniting the Fire Within: Stories of Healing, Hope & Humor, Inside Today's Young Breast Cancer Community: https://www.amazon.com/dp/B0BJVJ629F?ref_=pe_3052080_397514860More about Leslie: https://www.instagram.com/fireball7729/Get the free Wildfire email newsletter: https://www.wildfirecommunity.orgLearn about Wildfire writing workshops: https://www.wildfirecommunity.org/workshopsShop Wildfire merch & more: https://www.wildfirecommunity.org/shopSend your voice recording testimonial to editor@wildfirecommunity.org*Free* Get Wildfire and The Burn freebies here: https://www.wildfirecommunity.org/freeFollow Wildfire Magazine:https://www.instagram.com/wildfire_bc_magazine/https://www.facebook.com/wildfirecommunity

Join us as we recap the last few weeks at ILC! This year has already launched off great and we are seeing revival! This podcast is about living in the Overflow of God Blessings on his people and we just got to share! We wanna see revival, God kingdom grow, and see souls discipled into members of the body of Christ!

In today's episode, part of our MBC webinar series, we delve into the San Antonio Breast Cancer Symposium (SABCS). We aim to break down the overwhelming amount of information into digestible insights. We discuss key findings, particularly on inflammatory breast cancer (IBC) and invasive lobular carcinoma (ILC), with insights from Amy Parliman, a member of our MBC leadership team.Amy highlights the advancements in technology that outpace current treatment options and the importance of recognizing the unique challenges of diagnosing IBC and ILC due to their imaging difficulties. She shares that the symposium acknowledged these challenges and that there's growing research focusing on the genomic mutations specific to these types of breast cancer.We also touch on the significance of patient-centric care, reminding listeners that they have the ultimate say in their treatment decisions. Amy shares her personal experience with her treatment regimen and the importance of sticking with what works unless there's a compelling reason to change.The episode also covers the potential of contrasted mammograms and the need for different types of PET-CT scans for accurate diagnosis. We stress the importance of being informed and advocating for oneself, as treatments can vary based on individual cancer properties.As always, we remind our listeners that the information shared is from personal experiences and not a substitute for professional medical advice. We encourage reaching out to your medical care team with any questions or concerns.00:02:46 - Dr. Mankoff's Research on Imaging Technology00:04:02 - Genomic Mutations in Different Breast Cancer Types00:04:34 - Clinical Trials and Research Timelines00:04:56 - Genes Implicated in Inflammatory Breast Cancer00:06:02 - Imaging Challenges with Lobular Breast Cancer00:07:07 - Amino Acid Studies and PET-CT Imaging00:09:19 - Personalized Treatment and Informed QuestionsAttend a free virtual SurvivingBreastCancer.org event:https://www.survivingbreastcancer.org/eventsSurvivingBreastCancer.org's  Mission: To empower those diagnosed with breast cancer and their families from day one and beyond. Follow us on InstagramLaura and Will: https://www.instagram.com/laura_and_will/SurvivingBreastCancer.org: https://www.survivingbreastcancer.org/Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.Support the show

On this episode, Linda McKissack and Dana Gentry share more of their biggest takeaways from the I Love Coaching Summit they both attended recently.  They discuss their key takeaways from Dr. Ryan's talk on wealth building, and emphasize the importance of taking action, praying hard, and moving your feet in order to achieve success. They also highlight the significance of surrounding yourself with like-minded individuals who are committed to personal growth and development. Additionally, they mention the power of generosity and acting on impulses when opportunities arise. To sign up for the ILC 2024 Summit with a $600 discount, use code ELRE24 here  Get your Episode Guide here Check out our Everything Life and Influence course here

On this episode, Linda McKissack and Dana Gentry share their biggest takeaways from the I Love Coaching Summit they both attended recently.  They discuss what stood out to them most from each different speaker and subject, and how they plan to take action on what they learned.  They dive into health goals, social media goals, sales goals and business goals they've created for next year since listening to the speakers at the summit. To sign up for the ILC 2024 Summit with a $600 discount, use code ELRE24 here  To learn how to create great content from your phone, sign up for Tyler Hergott's webinar here Get your Episode Guide here Check out our Everything Life and Influence course here

Danny, Natalya, Bre and Phillip talked about HarvestFest at ILC 2023.  Over 3,000 people showed for this epic occasion! Link to Pictures of HarvestFest: https://photos.app.goo.gl/QB8AGCxKrNsAqEAk7Link to Drone Footage: CLICK HERE Check out the other podcasts...

Super fun time talking with a host of ILC teachers recapping the weekend.  We talked about bus ministry, the new Gentlemen’s corner, our 2nd teacher-lead Sunday and much more!  It was a fun one!...

In the rapidly changing world of tech, the hospitality industry can struggle to keep up. Today's guest is here to provide some guidance. Drawing on her 20 plus years of technology experience, she creates innovative experiences for guests and travelers. Joining the show this week is The Travel and Hospitality Industry Advisor at Salesforce, Jacqueline Nunley!Jacqui joins host Dan Ryan to look towards the future of the hospitality industry. They discuss the common challenges facing hoteliers when implementing technology, the ways AI can revolutionize customer experience, and how brands need to think about implementing AI. Takeaways:  Hospitality is an ever changing landscape. As guest expectations have changed, technology has advanced rapidly, creating a blank slate. This allows for the industry to redefine what hospitality means to them.  Because the hospitality industry is often fragmented, implementing new technologies can be a challenge. When looking for new solutions, leadership should prioritize technologies that can work cross-functionally. The level of repeatability and consistency in an experience needs to be tailored to the type of experience. Knowing what to expect can provide comfort to guests, but many guests often seek the unique experiences of the locations they visit.  When looking to implement tech into a hotel, the end goal should be on making the staff's jobs easier. By freeing up staff from mundane tasks that can easily be replaced, you allow them more time to focus on providing the human element to guests.  AI offers many benefits to the end customer, but it requires careful consideration of a guest's concerns. With many guests, there is a concern about the privacy of their data. Hotels need to provide a sense of security to ensure that guests trust the technology.  Implementing AI into the hospitality industry is not about replacing people's jobs, but rather about allowing them to better serve guests. Conversational AI can speed up support calls, drastically reducing customer frustrations. While AI has the potential to redefine the hospitality industry, it's adoption needs to be intentional. Instead of adding AI features because a competitor had, first assess if the use of that technology will add value to your customers.  Quote of the Show:“How are you engaging with your customers at the speed at which your customers are evolving?” - Jacqueline NunleyLinks: LinkedIn: https://www.linkedin.com/in/jacquelinesnunley/   Twitter: https://twitter.com/Jnunley12   Company website: https://www.salesforce.com/  Shout Outs: 01:09 - ILC: https://ilcongress.com/  43:45 - Jamie Dimon: https://www.linkedin.com/in/jamiedimon/  01:02:45 - Dreamforce: https://www.salesforce.com/dreamforce/  Ways to Tune In:  Spotify: https://open.spotify.com/show/0A2XOJvb6mGqEPYJ5bilPX Apple Podcasts: https://podcasts.apple.com/us/podcast/defining-hospitality-podcast/id1573596386 Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly93d3cuZGVmaW5pbmdob3NwaXRhbGl0eS5saXZlL2ZlZWQueG1s Amazon Music: ​​https://music.amazon.com/podcasts/8c904932-90fa-41c3-813e-1cb8f3c42419

Chris Welton was born under the worst conditions, which you can hear more about it in my interview with him. Chris is the VP of Sales at Certified Mortgage Planners. He's a Coach with ILC and has over 30 years of sales leadership. He's a recognized speaker and speaks all over the country. In addition to all this, he is the creator or host of The One Hand at a Time Podcast. His podcast was created to share life changing conversations with inspiring people from all walks of life. Chris explores the topics of personal growth, success, relationships, and mental health. He also creates an environment where people can feel safe and open up about their stories. He is a husband, father of two daughters and a son who passed in 2020. Dad Up! Dad Up YouTube: https://youtube.com/c/DadUpPodcast Dad Up Apple Podcast: https://podcasts.apple.com/us/podcast/dad-up-podcast/id1486764562 Dad Up Website: https://www.daduptribe.com/ Dad Up Instagram: https://www.instagram.com/daduppodcast/ Dad Up LinkTree: https://linktr.ee/Daduptribe Chris Welton LinkTree: VP of Sales/ Coach and Speaker | Linktree Chris Welton Instagram: https://instagram.com/onehandatatime --- Support this podcast: https://anchor.fm/daduppodcast/support